Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease

Hepato-Gastroenterology

Volumn 47, Issue 31, 2000, Pages 71-82

  Nikolaus, Susanna ^a   Fölsch, Ulrich R ^a   Schreiber, Stefan ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

5 ASA; Crohn's disease; Inflammation; Pharmacotherapy; Salazosulfapyridine; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; ARACHIDONIC ACID; CYTOKINE; CYTOKINE RECEPTOR; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESALAZINE; OXYGEN RADICAL; STEROID; TRANSCRIPTION FACTOR;

ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; B LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG EFFICACY; ENTERITIS; HUMAN; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; INTESTINE; LAMINA PROPRIA; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GLUCOCORTICOIDS; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE ACTIVATION; MESALAMINE; NF-KAPPA B; SULFASALAZINE;

EID: 0033975599     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (157)

1. 1 Svartz N: The treatment of 124 cases of ulcerative colitis with salazosulfapyridine and attempts of desensibilization in cases of hypersensitiveness to sulfa. Acta Med Scand 1948; 206:465-472.
2. 2 Azad Khan AK, Pirin J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. J Clin Invest 1977; 67:28-36.
3. 3 Klotz U, Maier K, Fischer C, Heinkel K: Therapeutic-efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Eng J Med 1980; 303:1499-1502.
4. 4 Klotz U: Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokin 1985; 10:285-302.
5. 5 Rasmussen S, Binder V, Maier K, et al: Treatment of Crohn's disease with peroral 5-aminosalicylic acid. Gastroenterology 1983; 85:1350-1353.
6. 6 Brogden RN, Sorkin ME: Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs 1989; 38:500-523.
7. 7 Singelton J, Law D, Kelley Jr M, Makhijian H, Shurdevant R: National cooperative Crohn's disease study: Adverse reactions to study drugs. Gastroenterology 1979; 77:870-882.
8. 8 Das K, Dubin R: Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokin 1976; 1:406-425.
9. 9 Taffet S, Das K: Sulfasalazine - adverse effects and desensitization. Dig Dis Sci 1983; 28:833-842.
10. 10 Toovey S, Hudson E, Hendry W, Levi A: Sulphasalazine and male infertility: Reversibility and possible mechanism. Gut 1981; 22:445-451.
11. 11 Hawkey CJ: Salicylates for the sulfa-sensitive patient with ulcerative colitis. Gastroenterology 1986; 90:1082-1084.
12. 12 Riley SA, Lecarpentier J, Mani V, Goodman MJ, Mandal BK, et al: Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. Gut 1987; 28:1008-1012.
13. 13 Harris J, Archampong EQ, Clark CG: The effect on water and electrolyte transport in the human colon measured in vivo and in vitro. Gut 1972; 13:855-861.
14. 14 Hanngren A, Hansson E, Svartz N, Ullberg S: Distribution and metabolism of salicyl-azosulphapyridine. Ada Med Scand 1963; 173:61-72, 391-399.
15. 15 Baum CL, Selhub J, Rosenberg IH: Antifolate actions of sulfasalazine on intact lymphocytes. J Lab Clin Med 1981, 97:779-788.
16. 16 Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW: National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77:847-869.
17. 17 Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H: European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86:249-266.
18. 18 Ballard PL, Carter JP, Graham BS, Baxter JD: A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. J Clin Endocrinol Metab 1975; 41:29-37.
19. 19 Täuber U: pharmakokinetik von Glukokorticoiden bei obstruktiven Atemwegserkrankungen. Vieweg: Brauschweig 1988; p. 23.
20. 20 Täuber U, Haack D, Nieuweboer B: The pharmacokinetics of fluocortolone and prednisone after intravenous and oral administration. Int J Pharmacol Ther Toxicol 1984; 22:48-57.
21. 21 Derendorf H: Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91A:22-28.
22. 22 Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T: Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331:836-841.
23. 23 Caesar I, Gross V, Roth M, Andus T, Schmidt C, Raedsch R, Weber A, Gierend M, Ewe K, Schölmerich J: Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group, Hepatogastroenterology 1997; 44:445-451.
24. 24 Lanyi B, Dries V, Dienes HP, Kruis W: Therapy of prednisone refactory collagenous colitis with budesonide. Int J Colorectal Dis 1999; 14:58-61.
25. 25 Lofberg R: Is potent tropical steroids the solution to collegenous colitis? Int J Colorectal Dis 1999; 14:62-64.
26. 26 Kumar MV, Tindall DJ: Transcriptional regulation of the steroid receptor genes. Prog Nucleic Acid Res Mol Biol 1998; 59:289-306.
27. 27 Lukiw WJ, Pelaez RP, Martinez J, Bazan NG: Budesonide epimer R or dexamethasone selectively inhibit platelet-activating factor-induced or interleukin 1beta-induced DNA binding activity of cis-acting transcription factors and cyclooxygenase-2 gene expression in human epidermal keratinocytes. Proc Natl Acad Sci USA 1998; 95:3914-3919.
28. 28 Saverymuttu SH, Chadwick VS, Hodgson HJ: Granulocyte migration in ulcerative colitis. Eur J Clin Invest 1985; 15:60-72.
29. 29 Saverymuttu SH, Peters AM, Lavender JP, Chadwick VS, Hodgson HS: In vivo assessment of granulocyte migration to diseased bowel in Crohn's disease. Gut 1985; 26:378-383.
30. 30 Schölmerich J, Schmidt E, Schumichen C, et al: Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m hexamethyl propylene amine oxine as leukocyte label. Gastroenterology 1988; 95:1287-1293.
31. 31 Pullman WE, Sullivan PJ, Barratt PJ, et al: Assessment of inflammatory bowel disease activity by technetium 99m phagocyte scanning. Gastroenterology 1988; 95:989-996.
32. 50 Sharon P, Ligumsky M, Rachmilewitz D, et al: Role of prostaglandins in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75:638-640.
33. 51 Gould SR: Assay of prostaglandin like substances in feces and their measurement in ulcerative colitis. Prostaglandins 1981; 11:489-497.
34. 52 Gould SR, Brash AR, Conolly ME, et al: Studies of prostaglandins and sulphasalazine in ulcerative colitis. Prostaglandins Leukotrienes Med 1981; 6:165-182.
35. 53 Lauritsen K, Laursen LS, Bukhave K, et al: Effects of systemic prednisolone on arachidonic acid metabolites determined by equilibrium in vivo dialysis of rectum in severe relapsing ulcerative colitis. Gastroenterology 1985; 88:A1466. (Abstract)
36. 54 Rampton DS, Sladen GE, Youlten LY: Rectal mucosal prostaglandin E2 release and its relation to disease activity: electrical potential differences and treatment in ulcerative colitis. Gut 1980; 21:591-596.
37. 55 Zifroni A, Treves AJ, Sachar DB, et al: Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut 1983; 24:659-664.
38. 56 Green SE, Bradburn DM, Varna JS, Burn J: Hereditary non-polyposis colorectal cancer. Int J Colorectal Dis 1998; 123:3-12.
39. 57 Ligumsky M, Karmeli F, Sharon P, et al: Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981; 81:444-449.
40. 58 Lauritsen K, Laursen LS, Bukhave K, et al: Effects of topical 5-ASA and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91:837-844.
41. 59 Rampton DS, Hawkey CJ: Prostaglandins in ulcerative colitis. Gut 1984; 25:1399-1413.
42. 60 Flower RJ, Blackwell CJ: Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979; 278:456-459.
43. 61 Hawkey CJ: Evidence that prednisolone is inhibitory to the cyclooxygenase activity of human rectal mucosa. Prostaglandins 1982; 23:397-409.
44. 62 Gilat T, Ratan J, Rosen P, et al: Prostaglandins and ulcerative colitis. Gastroenterology 1979; 77:1083.
45. 63 Campieri M, Lanfranci GA, Bazzochi G, et al: Prostaglandins, indomethacin and ulcerative colitis. Gastroenterology 1980; 78:193.
46. 64 Levy N, Gaspar E: Rectal bleeding and indomethacin suppositories. Lancet 1975; 1:577.
47. 65 Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231:232-235.
48. 66 Richard CS, Berk T, Bapat BV, Haber G, Cohen Z, Gallagher S: Sulindac for periampullary polyps in FAP patinets. Int J Colorectal Dis 1997; 12:14-18.
49. 67 Shpitz B, Bromstein Y, Kanin N, Shaler M, Buklan G, Bernheim J: Chemopreventive effect of aspirin on growth of aberrant crypt foci in rats. Tnt J Colorectal Dis 1998; 13:169-172.
50. 32 Rampton DS, Sladen GE: Prostaglandin synthesis inhibitors in ulcerative colitis: flubiprofen compared with conventional treatment. Prostaglandins 1981; 21:417-425.
51. 33 Rampton DS, Sladen GE: The relationship between rectal mucosa prostaglandin production and water and electrolyte transport in ulcerative colitis. Digestion 1984; 30:13-22.
52. 34 Tertioglu T, Valti T, Tetelman S: The effect of prostaglandin Ei on experimental colitis int he rat. Int J Colorectal Dis 1997; 12:63-66.
53. 35 Stenson WF, Parker CW: Leukotrienes. Adv Intern Med 1984; 30:175-199.
54. 36 Buckell NA, Gould SR, Day DW, Lennard Jones JE, et al: Controlled trial of sodium cromoglycate in chronic persistent ulcerative colitis. Gut 1978; 19:1140-1143.
55. 37 Kuhbacher T, Schreiber S, Runkel N: Pouchitis: pathophysiology and treatmnent. Int J Colorectal Dis 1998; 13(5-6):196-207.
56. 38 Goppelt-Strube M, Schaefer D, Habenicht AJ: Differential regulation of cyclo-oxygenase-2 and 5-lipoxygenase-activating protein (FLAP) expression by glucocorticoids in monocytic cells. Br J pharmacol 1997; 122:619-624.
57. 39 Crocker IC, Zhou CY, Bewtra AK, Kreutner W, Townley RG: Glucocorticosteroids inhibit leukotriene production. Ann Allergy Asthma Immunol 1997; 78:497-505.
58. 40 Powell WS, Xu LJ, Martin JG: Effects of dexamethasone on leukotriene synthesis and airway response to antigen and leukotriene D4 in rats. Am J Respir Crit Care Med. 1995; 151:1143-1150.
59. 41 Hawkey CJ, Truelove SC: Inhibition of prostaglandin synthetase in human rectal mucosa. Gut 1983; 24:213-217.
60. 42 Hawkey CJ, Boughton-Smith NK, Whittle BJR: Modulation of human colonic arachidonic acid metabolism by sulphasalazine. Dig Dis Sci 1985; 130:1161-1165.
61. 43 Sharon P, Stenson WF: Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86:453-460.
62. 44 Mueller HW, O'Flaherty, Wykle RL: The molecular species distribution of platelet-activating factor synthesized by rabbit and human neutrophils. J Biol Chem 1984; 259:14554-14559.
63. 45 Ludwig JC, Pinckard RN: Diversity in the chemical structures of neutrophil-derived platelet activating factors. In: Winslow CM, Lee JL (Eds.). New horizons in platelet activating factor research. New York: John Wiley and Sons, 1985; pp. 59-71.
64. 46 Oda M, Satouchi K, Yasunaga K, et al: Molecular species of platelet-activating factor generated by human neutrophils challenged with ionophore A23187. J Immunol 1985; 134:1090-1093.
65. 47 Weintraub ST, Ludwig JC, Mott GE: Fast atom bombardment-mass spectrometric identification of molecular species of platelet-activating factor produced by stimulated human polymorphonuclear leukocytes. Biochem Biophys Res Commun 1985; 129:868-876.
66. 48 Satouchi K, Oda M, Yasunaga K, et al: Evidence for the production of 1-acyl-2-acetyl-sn-glyceryl-3-phosphorylcholine concomitantly with platelet activating factor. Biochem Biophys Res Commun 1985; 128:1409-1417.
67. 49 Ramesha CS, Pickett WC: Species-specific variations in the molecular heterogenity of the platelet activating factor. J Immunol 1987; 138:1559-1563.
68. 68 McManus LM, Hanahan DJ, Demopoulos CA, et al: Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGPEC), a synthetic platelet activating factor (PAF), in the rabbit. J Immunol 1980; 124:2919-2924.
69. 69 Pinckard RN, McManus LM, Demopoulos CA, et al: Molecular pathobiology of acetyl glyceryl ether phosphorylcholine (AGEPC): Evidence for the structural identitiy with platelet activating factor (PAF). J Reticuloendothel Soc 1980; 28:95s-103s.
70. 70 Shaw JO, Pinckard RN, Ferrigni KS, McManus LM, et al: Activation of human neutrophils with 1-O-hexadecyl/oxtadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor). J Immunol 1981; 127:1250-1255.
71. 71 Hartung HP: Acetyl glyceryl ether phosphorylcholine (platelet activating factor) mediates heightened metabolic activity in macrophages. FEBS Lett 1983; 160:209-212.
72. 72 Hartung HP, Parnham MJ, Winkelmann J, et al: Platelet activating factor (PAF) induces the oxidative burst in macrophages. Int J Immunopharmacol 1983; 5:115-121.
73. 73 Yasaka T, Boxer LA, Baehner RL: Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF). J Immunol 1982; 128:1939-1944.
74. 74 Ingraham LM, Coates TD, Allen JM, et al: Metabolic, membrane and functional responses of human polymorphonuclear leukocytes to platelet-activating factor. Blood 1982; 59:1259-1266.
75. 75 Gay JC, Beckman JK, Zaboy KA, et al: Modulation of neutrophil oxidative responses to soluble stimuli by platelet-activating factor. Blood 1986; 67:931-936.
76. 76 Lin AH, Morton DR, Gorman RR: Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes. J Clin Invest 1982; 70:1058-1065.
77. 77 Bussolino F, Aglietta M, Sanavio R, et al: Alkyl-etherphosphoglycerides influence calcium into human endothelial cells. J Immunol 1985; 135:2748-2753.
78. 78 Brock TA, Gimbrone MA Jr: Platelet activating factor alters calcium homeostasis in cultured vascular endothelial cells. Am J physiol 1986; 252:H1086-H1092.
79. 79 Brunynzeel PLB, Koenderman L, Lif PTM, et al: Platelet activating factor (PAF-acether) induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils. Pharmacol Res Commun 1986; 18:61-69.
80. 80 O'Flaherty JT: Neutrophil degranulation: Evidence pertaining to its mediation by the combined effects of leukotriene B4, platelet-activating factor and 5-HETE. J Cell Physiol 1985; 122:229-239.
81. 81 O'Flaherty JT, Wykle RL, Thomas MJ, et al: Neutrophil degranulation responses to combinations of arachidonate metabolites and platelet-activating factor. Res Commun Chem Pathol Pharmacol 1984; 43:3-23.
82. 82 Humphrey DM, McManus LM, Hanahan DJ, et al: Morphologic basis of increased vascular permeability induced by acetyl glyceryl ether phosphorylcholine. Lab Invest 1984; 50:16-25.
83. 83 Sanchez-Crespo M, Alonso F, Inarrea P, et al: Vascular actions of synthetic PAF-acether (a synthetic platelet activating factor) in the rat: Evidence for a platelet independent mechanism. Immunopharmacology 1982; 4:173-185.
84. 84 Humphrey DM, McManus LM, Satouchi K, et al: Vasoactive properties of acetyl glyceryl ether phosphorylcholine (AGEPC) and AGEPC analogues. Lab Invest 1982; 46:422-427.
85. 85 Hwang SB, Chang-Ling L, Lam MH, et al: Characterization of cutaneous vascular permeability induced by platelet activating factor (PAF) in guinea pigs and rats and its inhibition by a PAF receptor antagonist. Lab Invest 1985; 52:617-630.
86. 86 Archer CB, MacDonald DM, Morley J, et al: Effects of serum albumin, indomethacin and histamine H1-antagonists on PAF-acether-induced inflammatory responses in the skin of experimental animals and man. Br J Pharmacol 1985; 85:109-113.
87. 87 Eliakim R, Karmeli F, Razin E, et al: Role of platelet-activating factor in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazine and prednisone. Gastroenterology 1988; 95:1167-1172.
88. 88 Eliakim R, Karmeli F, Razin E, Rachmilewitz D: Role of platelet activating factor in ulcerative colitis. Gastroenterology 1988; 95:1167-1172.
89. 89 Sobhani I, Hochlaf S, Denizot Y, et al: PAF as an activity marker in Crohn's disease. Gastroenterology 1991; 100:A616.
90. 90 Mayberry JF: Recent epidemiology of ulcerative colitis and Crohn's disease. Int J Colorectal Dis 1989; 4:59-66.
91. 91 Sun S, Hsueh W: Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest 1988; 81:1328-1331.
92. 92 Elson CO: The basis of current and future therapy for inflammatory bowel disease. Am J Med 1996; 100:656-662.
93. 93 Klebanoff SJ: Phagocytic cells: Products of oxygen metabolism. In: Gallin JI, Goldstein IM, Snyderman R, (Eds.). Inflammation. New York: Raven Press 1988; pp. 391-445.
94. 94 Forehand JR, Nauseef WM, Johnston RB Jr: Inherited disorders of phagocyte killing. In: Scriver CR, et al, (Eds.). The Metabolic Basis of Inherited Disease. 6th Edition. New York: McGraw-Hill, 1989; p. 2779.
95. 95 Suematsu M, Suzuki M, Kitahora T, et al: Increased respiratory burst of leukocytes in inflammatory bowel diseases - the analysis of free radical generation by using chemiluminescence probe. J Clin Lab Immunol 1987; 24:125-128.
96. 96 Baldassano RN, Schreiber S, Johnston RB, Muraki T, MacDermott RP: Monocytes of patients with Crohn's disease are primed for accentuated release of toxic oxygen metabolites: possible role for endotoxin. Gastroenterology, 1993; 105:60-66.
97. 97 Blaser MJ, Miller RA, Lacher J, et al: Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 1984; 87:888-894.
98. 98 Palmer KR, Duerden BI, Holdsworth CD: Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. Gut 1980; 21:851-854
99. 99 Aoki K: A study of endotoxemia in ulcerative colitis and Crohn's disease: I. Clinical Study Acta Med Okayama 1978; 32:147-158.
100. 100 Ahnfelt-Ronne I, Nielson OH, Christensen A, et al: Clinical evidence supporting the radical scavenger mechanism of 5-ASA. Gastroenterology 1990; 98:1162-1169.
101. 101 Miyachi Y, Yoshioka A, Imamura S, et al: Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987; 28:190-195.
102. 102 Williams JG, Hallett MB: Effect of sulphasalazine and its active metabolite, 5-amino-salicylic acid, on toxic oxygen metabolite production by neutrophils. Gut 1989; 30:1581-1587.
103. 103 Verapaget HW, Aparicio-Pages MN, Verver S, Edelbroek PM, Hafkenscheid JCM, et al: Influence of sulphasalazine and mesalazine on cellular and biochemical oxygen metabolite production. Scand J Gastroenterol 1991; 26:779-786.
104. 104 Tamai H, Kachur JF, Grisham MB, Gaginella TS: Scavenging effect of 5-aminosalicylic acid on neutrophil-derived oxidants. Biochem Pharmacol 1991; 41:1001-1006.
105. 105 Greenfield SM, Punchard NA, Thompson Rph: Inhibition of red cell membrane lipid peroxidation by sulfasalazine and 5-aminosalicylic acid. Gut 1991; 32:1156-1159.
106. 106 Raedler A, Fraenkel S, Klose G, et al: Involvement of the immune system in the pathogenesis of Crohn's disease. Expression of the T9 antigen on peripheral immunocytes correlated with the severity of the disease. Gastroenterology 1985; 88:978-983.
107. 107 Raedler A, Fraenkel S, Klose G, et al: Elevated numbers of peripheral T cells in inflammatory bowel diseases displaying T9 antigen and Fc alpha receptors. Clin Exp Immunol 1985; 60:518-524.
108. 108 Schreiber S, Nash GS, Raedler A, et al: Human lamina propria mononuclear cells are activated in inflammatory bowel disease. In: Tsuchiya M, Nagura H, Hibi T, Moro I, (Eds.). Frontiers of mucosal immunology. Amsterdam: Elsevier, 1991; pp. 749-753.
109. 109 Raedler A, Schreiber S, Schulz KH, et al: Activated Fc-alpha T-cells in Crohn's disease are involved in regulation of IgA. Adv Exp Med Biol 1988; 237:665-673.
110. 110 Raedler A, Bredow G, Kirch W, et al: In vivo activated T cells in autoimmune disease. J Clin Lab Immunol 1986; 19:181-186.
111. 111 Pallone F, Fais S, Squarcia O, et al: Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 1987; 28:745-753.
112. 112 Fais S, Pallone F, Squarcia O, et al: HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease, I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clin Exp Immunol 1987; 68:605-612.
113. 113 Geboes K, Rutgeerts P, Penninckx F, Desmet V, Vantrappen G: Changes in small intestinal epithelial expression of MHC class II antigen after terminal ileal resection for Crohn's disease. Int J Colorectal Dis 1988; 3:102-108.
114. 114 Tytgat GN, Mulder CJ: The etiology of Crohn's disease. Int J Colorectal Dis 1986; 1:188-192.
115. 115 Allison CM, Poulter LW, Dhillon AP, et al: Immunohistological studies of surface antigen on colonic lymphoid cells in normal and inflamed mucosa. Gastroenterology 1990; 99:421-430.
116. 116 Schreiber S, MacDermott RP, Raedler A, et al: Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 1991; 101:1020-1030.
117. 117 Schreiber S, Raedler A, Conn AF, Rombeau JL, MacDermott RP: Increased release of soluble Interleukin-2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease. Gut 1992; 32:236-241.
118. 118 James SP, Murakawa Y, Kanof ME, et al: Role of intestinal T-cells and intestinal lymphokine production in inflammatory bowel disease. In: Tsuchiya M, Nagura H, Hibi T, Moro I (Eds.). Frontiers of mucosal immunology. Amsterdam: Elsevier, 1991; pp. 727-731.
119. 119 Stevens C, Walz G, Bath C, Strom TB: The effects of sulfasalazine (SS) and 5-aminosalicylic acid (5-ASA) on T cell activation genes and proteins. Gastroenterology 1990; 98:A475.
120. 120 Crotty B, Hoang P, Dalton HR, Jewell DP: Salicylates used in inflammatory bowel disease and colchicine impair interferon-γ induced HLA-DR expression. Gut 1992; 33:59-64.
121. 121 Schreiber S, Berghaus D, Raedler A: Unpublished observation.
122. 122 MacDermott RP, Schloemann SR, Bertovich MJ, Nash GS, Peters M, Stenson W: Inhibition of antibody synthesis by 5-aminosalicyclic acid. Gastroenterology 1989, 96:442-448.
123. 149 Nielsen OH, Ahnfelt-Ronne I: 4-Aminosalicylic acid in contrast to 5-aminosalicylic acid has no effect on arachidonic acid metabolism in human neutrophils, or on the free radical 1,1 diphenyl-2-picrylhydrazyl. Pharmacol Toxicol 1988; 62:223-226.
124. 123 Lenardo MJ, Baltimore D: NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58:227-229.
125. 124 Baldwin AS: The NF-KB an I-KB proteins: New discoveries and insights. Ann Rev Immunol 1996; 14:649-681.
126. 125 Schottelius AJ, Balbwin AS: A role for transcription factor NF-KB in intestinal inflammation. Int J Colorectal Dis 1999; 14:18-28,
127. 126 Brown K: Gerstberg S, Carlson L, Franzoso G, Siebenlist U: Control of IKB-α proteolysis by site-specific signal induced phosphorylation. Science 1995; 267:1485-1487.
128. 127 Traenckner EB, Wilk S, Baeurerle PA: A proteasome inhibitor prevents activation of NF-kappa B and stabilizes an newly phosphorylated form of I-kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994; 13:5433-5441.
129. 128 Scherer DC, Brockman JA, Chen Z, Maniatis T, Ballard DW: Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci USA 1995; 92:11259-11263.
130. 129 Schreiber S, Nikolaus S, Hampe J: Activiation of nuclear factor kappa B in inflammatory bowel disease. Gut 1998; 42:477-485.
131. 130 Nikolaus, S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S: Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998; 42:470-476.
132. 131 Neurath MF, Petterson S, Meyer zum Büschenfelde KH, Strober W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-KB abrogates established experimental colitis in mice. Nature Medicine 1996; 2:998-1004.
133. 132 Scheinman RI, Cogswell PC, Lofquist AK, Baldwin Jr AS: Role of transcriptional activation by IkB in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283-286.
134. 133 Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosupression by glucocorticoids: inhibition of NFkB activity through induction of IkB synthesis. Science 1995; 270:286-290.
135. 134 Hampe J, Schottelius A, Wedel S, Nikolaus S, Raedler A, Lochs H, Schreiber S: Downregulation of the NFkB/IkB system in IBD patients on chronic steroid medication. Gut 1997; 41(S3):A69.
136. 135 Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265:956-959,
137. 136 Bitko V, Velazquez A, Yang L, Yang YC, Barik S: Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa-B and is inhibited by sodium salicylate and aspirin. Virology 1997; 232:369-378.
138. 137 Stange C, Ramirez I, Gomez I, Jordana X, Holuigue L: phosphorylation of nuclear proteins directs binding to salicylic acid responsive elements. Plant J 1997; 11:1315-1324.
139. 138 Osnes LT, Foss KB, Joo GB, Okkenhaug C, Westvik AB, Ovstebo R, Kierulf P: Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-kappa Blc-Rel nuclear translocation, and synthesis of tissue factor (TF) and tumor necrosis factor alpha (TNF-alpha) in human monocytes. Thromb Haemost 1996; 76:970-976.
140. 139 Oeth P, Mackman N: Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. Blood 1995; 86:4144-4152.
141. 140 Takashiba S, Van Dyke TE, Shapira L, Amar S: Lipopolysaccharide-inducible and salicylate, sensitive nuclear factor (s) on human tumor necrocis factor alpha promoter. Infect Immun 1995; 63:1529-1534.
142. 141 Baert FJ, Rutgeerts PR: Anti-TNF strategies in Crohn's disease: Mechanisms, clinical effects, indications. Int J Colorectal Dis 1999; 14:47-51.
143. 142 Takashiba S, Van Dyke TE, Amar S: Inhibition of nuclear factor kappa B subunit p65 mRNA accumulation in lipopolysaccharide-stimulated human monocytic cells treated with sodium salicylate. Oral Microbiol Immunol 1996; 11:420-424.
144. 143 Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T: Salicylates inhibit I kappa B-alpha posphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 1996; 156:3961-3969.
145. 144 Schwenger P, Alpert D, Slotnik EY, Vilcek J: Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced I kappa B alpha phosphorylation and degradation. Mol Cell Biol 1998; 18:78-84.
146. 145 Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101:1163-1174.
147. 146 Mitchell JA, Saunders M, Barnes PJ, Newton R, Belvisi MG: Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol 1997; 51:907-912.
148. 147 Hanauer SB, Meyers S: Management of Crohn's disease in adults. Am J Gastroenterol 1997; 92:559-566.
149. 148 Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, Brunetti G, Miglioli M, Barbara L: Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. Int J Colorectal Dis 1990; 5:79-81.
150. 150 Johnson M: Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998; 101:S434-S439.
151. 151 Hogger P, Rohdewald P: Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59:597-602.
152. 152 Dahlberg E, Thalen A, Brattsand R, Gustafsson JA, Johansson U, Roempke K, Saartok T: Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids. Mol Pharmacol 1984; 25:70-78.
153. 153 Hugot JP, Touali H, Lesage S, Thomas G: Etiology of the inflammatory bowel diseases. Int J Colorectal Dis 1999; 14:2-9.
154. 154 Schreiber S, Hampe: Genetics in gastrointestinal disease: How much can we learn from molecular analysis? Int J Colorectal Dis 1999; 14:10-12.
155. 155 Schreiber S: Morbis Crohn und colitis ulcerosa-Aspekte aus pathophysiologic. Leber Magen Daem 1997; 29(53):34-3.
156. 156 Schreiber S, Nikolaus S, Hampe J: Activation of nuclear factor kappa B in inflammatory bowel disease. Gut 1998; 42:477-485.
157. 157 Schottelius AJG, Mayot MW, Sartor B, Baldwin AS: Interleukin-10 signaling blocks inhibitor of KB kinase activity and nuclear factor KB binding. J Biol Chem 1999; 274:31868-31874.